More tools:Markets·Screener·Research·Chat

Neuphoria Therapeutics Inc. Common Stock (NEUP) Financial Statements

Neuphoria Therapeutics Inc. Common Stock
SIC 2834 · PHARMACEUTICAL PREPARATIONS
FIGI BBG01RFZ8667
XNAS · usd
3.75▼ 0.02 (-0.53%)
As of 2026-09-08
Valuation
Market Cap
Enterprise Value
Trailing P/E—
Price / Sales
EV / Revenue
EV / EBITDA
Financial Highlights
Revenue (TTM)
Net Income (TTM)
EBITDA
Diluted EPS (TTM)
EBITDA Margin
Net Debt
Trading Information
Previous Close3.77
Day's Range3.72 – 3.84
52-Week Range3.19 – 21.40
Volume22.6K
Avg Volume48.5K
Share Statistics
Shares Outstanding
Employees8
ExchangeXNAS
Listed2021-12-16
Share count as of May 14, 2026
Loading Income Statement…
Key questions about Neuphoria Therapeutics Inc. Common Stock (NEUP)
What is Neuphoria Therapeutics Inc. Common Stock's Market Cap?
Neuphoria Therapeutics Inc. Common Stock's Market Cap is $20.3M, based on as-reported figures from SEC (XBRL) filings.
What is Neuphoria Therapeutics Inc. Common Stock's Enterprise Value?
Neuphoria Therapeutics Inc. Common Stock's Enterprise Value is $826.4K, based on as-reported figures from SEC (XBRL) filings.
What is Neuphoria Therapeutics Inc. Common Stock's Price / Sales?
Neuphoria Therapeutics Inc. Common Stock's Price / Sales is 1.3×, based on as-reported figures from SEC (XBRL) filings.
What is Neuphoria Therapeutics Inc. Common Stock's EV / Revenue?
Neuphoria Therapeutics Inc. Common Stock's EV / Revenue is 0.1×, based on as-reported figures from SEC (XBRL) filings.
What is Neuphoria Therapeutics Inc. Common Stock's EV / EBITDA?
Neuphoria Therapeutics Inc. Common Stock's EV / EBITDA is n/m, based on as-reported figures from SEC (XBRL) filings.
What is Neuphoria Therapeutics Inc. Common Stock's Revenue (TTM)?
Neuphoria Therapeutics Inc. Common Stock's Revenue (TTM) is $15.6M, based on as-reported figures from SEC (XBRL) filings.
What is Neuphoria Therapeutics Inc. Common Stock's Net Income (TTM)?
Neuphoria Therapeutics Inc. Common Stock's Net Income (TTM) is -$17.5M, based on as-reported figures from SEC (XBRL) filings.
What is Neuphoria Therapeutics Inc. Common Stock's EBITDA?
Neuphoria Therapeutics Inc. Common Stock's EBITDA is -$16.1M, based on as-reported figures from SEC (XBRL) filings.
What is Neuphoria Therapeutics Inc. Common Stock's Diluted EPS (TTM)?
Neuphoria Therapeutics Inc. Common Stock's Diluted EPS (TTM) is -3.23, based on as-reported figures from SEC (XBRL) filings.
What is Neuphoria Therapeutics Inc. Common Stock's EBITDA Margin?
Neuphoria Therapeutics Inc. Common Stock's EBITDA Margin is -102.9%, based on as-reported figures from SEC (XBRL) filings.
Showing the most recent year. Subscribe for full statement history.
Income Statement(in thousands of USD, except per-share data)
Source: Akyla.ai
Line ItemMar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023
License revenue———
Operating expenses:
Research and development
General and administrative
Restructuring costs——
Total operating expenses
% of revenue———-43881.7%
(Loss) income from operations
% of revenue———43981.7%
Other income (loss):
Interest income, net
(Loss) gain on foreign currency transactions
Research and development incentive award—
Gain (loss) on fair value adjustments
Total other income (expense)
(Loss) income before income taxes
Income tax benefit
Net (loss) income
% of revenue———66960.6%
Other comprehensive income (loss)
Unrealized gain (loss) on foreign currency translation
Total other comprehensive income (loss)
Total comprehensive income (loss)
Net (loss) income per share - basic
Net (loss) income per share - diluted—